Glyza 5 mg (Tablet)

Unit Price: ৳ 35.00 (3 x 10: ৳ 1,050.00)
Strip Price: ৳ 350.00

Medicine Details

Category Details
Generic Saxagliptin
Company Ibn sina pharmaceuticals ltd
Also available as

Indications

  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Pharmacology

  • Inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels
  • Elevates the circulating levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in pancreatic beta-cells
  • Reduces fasting and postprandial plasma glucose concentration in patients with type 2 diabetes mellitus

Dosage

  • Recommended dosage of 2.5 mg or 5 mg once daily regardless of meals
  • No dosage adjustment for patients with mild renal impairment (CrCl > 50 mL/min)
  • Dosage of 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (CrCl ≤ 50 mL/min)
  • Dosage adjustment to 2.5 mg once daily when coadministered with strong CYP3A4/5 inhibitors
  • Lower dose of insulin secretagogue or insulin may be required when used in combination with them

Administration

  • May be taken with or without food

Interaction

  • Increased risk of hypoglycemia with concomitant sulfonylureas; dose reduction may be necessary
  • Increased serum levels with CYP3A4/5 inhibitors
  • Concomitant CYP3A4 inducers may reduce the glycemic lowering effect

Contraindications

  • Type 1 diabetes
  • Diabetic ketoacidosis

Side Effects

  • Pancreatitis
  • Heart failure
  • Hypoglycemia with concomitant use of sulfonylurea or insulin
  • Hypersensitivity reactions
  • Severe and disabling arthralgia
  • Bullous pemphigoid

Pregnancy & Lactation

  • Category B

Precautions & Warnings

  • Moderate and severe renal impairment
  • Pregnancy and lactation

Use in Special Populations

  • No dosage adjustment needed for mild renal impairment
  • Dosage of 2.5 mg once daily for moderate to severe renal impairment, including ESRD requiring hemodialysis
  • No dosage adjustment needed for hepatic impairment

Therapeutic Class

  • Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

  • Store between 20-25°C

Related Brands